Health Care

Commentary

Drugmakers Are Embracing Direct-To-Consumer Sales. That’s Fantastic News For Patients.

Several Big Pharma companies have started selling their drugs directly to consumers (DTC). This shift — driven in part by President Trump’s push for lower drug prices and fewer middlemen — has garnered relatively little media coverage. But the implications for American patients, employers, and the healthcare system as a ...
Commentary

Obamacare Premiums Are Climbing Again. But Americans Finally Have An Alternative

Get ready to pay more for insurance coverage through Obamacare’s exchanges. The median premium increase for plans from 105 insurers in 19 states and the District of Columbia will be 15% in 2026, according to the Kaiser Family Foundation. That’s more than double the median premium increase of 7% this ...
Commentary

Drug Tariffs Cure Nothing and Are a Tax Increase

President Donald Trump has made no secret of his desire for sweeping tariffs on pharmaceuticals. Last month, the president threatened tariffs as high as 200% on imported drugs. The trade deal with the European Union (EU) finalized July 27 includes a 15% levy on medicines imported from the continent. Drug ...
Commentary

We don’t need socialism to cut drug prices. Americans get a good deal

Nearly nine in every 10 Americans say that prescription drug prices are too high. Yet the average prescription costs less in the U.S. than in other developed countries, according to a new study from professor Tomas Phillipson, the former chairman of the White House Council of Economic Advisers. That finding ...
Health Care

New PRI Study: Reforms to Expand PACE Program Could Save Taxpayers Billions, Improve Senior Care

SACRAMENTO – A new issue brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute calls for reforms to expand the reach of the Program of All-Inclusive Care for the Elderly (PACE), a joint Medicare and Medicaid program that delivers comprehensive medical and social ...
Commentary

Medicaid At 60: A Safety Net In Need Of Serious Repair

Today, Medicaid turns 60. But this will be no diamond jubilee. What began in 1965 as a modest safety-net program has ballooned into the largest health entitlement in the country, covering nearly 80 million Americans, costing close to $900 billion a year, and delivering poor value for both patients and ...
Commentary

Doctors Deserve More Than a Token Pay ‘Raise’ from Medicare

The Trump administration is giving doctors a modest pay raise. A proposal released this month by the Centers for Medicare and Medicaid Services would, among other things, implement the 2.5% hike in Medicare physician reimbursement established by the One Big Beautiful Bill Act, which President Trump signed into law July ...
Blog

Read part 3 of a series on drug pricing

Regulations, Not Anticompetitive Actions, Are Obstructing Drug Competition

The flaws driving up costs across the broader health care landscape are also driving up the costs for innovative drugs. After all, pharmaceuticals are an integral component used in combination with the broader healthcare system. As a result, spending on medicines both influences and is influenced by the spending on ...
Commentary

America Doesn’t Have Enough Doctors. Medicare Is Making That Worse.

The United States is facing a shortage of 37,000 physicians, according to the latest research from the Association of American Medical Colleges. That deficit will more than double to 86,000 doctors by 2036. Medicare’s chronically low reimbursement rates deserve at least part of the blame. According to the American Medical ...
Commentary

How Price Controls Make a Healthy Drug Market Sick

The unspoken assumption behind the prescription drug price controls at the heart of the Democrats’ August 2022 Inflation Reduction Act (IRA) is that the pharmaceutical market is broken. According to this view, drugmakers have the power to charge whatever they want. Only a sweeping system of government price-setting can put ...
Commentary

Drugmakers Are Embracing Direct-To-Consumer Sales. That’s Fantastic News For Patients.

Several Big Pharma companies have started selling their drugs directly to consumers (DTC). This shift — driven in part by President Trump’s push for lower drug prices and fewer middlemen — has garnered relatively little media coverage. But the implications for American patients, employers, and the healthcare system as a ...
Commentary

Obamacare Premiums Are Climbing Again. But Americans Finally Have An Alternative

Get ready to pay more for insurance coverage through Obamacare’s exchanges. The median premium increase for plans from 105 insurers in 19 states and the District of Columbia will be 15% in 2026, according to the Kaiser Family Foundation. That’s more than double the median premium increase of 7% this ...
Commentary

Drug Tariffs Cure Nothing and Are a Tax Increase

President Donald Trump has made no secret of his desire for sweeping tariffs on pharmaceuticals. Last month, the president threatened tariffs as high as 200% on imported drugs. The trade deal with the European Union (EU) finalized July 27 includes a 15% levy on medicines imported from the continent. Drug ...
Commentary

We don’t need socialism to cut drug prices. Americans get a good deal

Nearly nine in every 10 Americans say that prescription drug prices are too high. Yet the average prescription costs less in the U.S. than in other developed countries, according to a new study from professor Tomas Phillipson, the former chairman of the White House Council of Economic Advisers. That finding ...
Health Care

New PRI Study: Reforms to Expand PACE Program Could Save Taxpayers Billions, Improve Senior Care

SACRAMENTO – A new issue brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute calls for reforms to expand the reach of the Program of All-Inclusive Care for the Elderly (PACE), a joint Medicare and Medicaid program that delivers comprehensive medical and social ...
Commentary

Medicaid At 60: A Safety Net In Need Of Serious Repair

Today, Medicaid turns 60. But this will be no diamond jubilee. What began in 1965 as a modest safety-net program has ballooned into the largest health entitlement in the country, covering nearly 80 million Americans, costing close to $900 billion a year, and delivering poor value for both patients and ...
Commentary

Doctors Deserve More Than a Token Pay ‘Raise’ from Medicare

The Trump administration is giving doctors a modest pay raise. A proposal released this month by the Centers for Medicare and Medicaid Services would, among other things, implement the 2.5% hike in Medicare physician reimbursement established by the One Big Beautiful Bill Act, which President Trump signed into law July ...
Blog

Read part 3 of a series on drug pricing

Regulations, Not Anticompetitive Actions, Are Obstructing Drug Competition

The flaws driving up costs across the broader health care landscape are also driving up the costs for innovative drugs. After all, pharmaceuticals are an integral component used in combination with the broader healthcare system. As a result, spending on medicines both influences and is influenced by the spending on ...
Commentary

America Doesn’t Have Enough Doctors. Medicare Is Making That Worse.

The United States is facing a shortage of 37,000 physicians, according to the latest research from the Association of American Medical Colleges. That deficit will more than double to 86,000 doctors by 2036. Medicare’s chronically low reimbursement rates deserve at least part of the blame. According to the American Medical ...
Commentary

How Price Controls Make a Healthy Drug Market Sick

The unspoken assumption behind the prescription drug price controls at the heart of the Democrats’ August 2022 Inflation Reduction Act (IRA) is that the pharmaceutical market is broken. According to this view, drugmakers have the power to charge whatever they want. Only a sweeping system of government price-setting can put ...
Scroll to Top